RPTX: רווח נקי למניה ב-12 החודשים האחרונים reparerx.com

Net income per share for the last four quarters in GURU.Markets features a linear chart containing yield data for Repare Therapeutics (RPTX), which is based on partnerships with pharma giants. Effective capital and scientific portfolio management, combined with a strong team of researchers, confirm the model's resilience. Meanwhile, the -1.69 mark records this indicator, allowing for a real-time assessment of the business's actual return without reporting time lags.

Repare Therapeutics (RPTX) develops highly scalable cancer therapies where patents provide the potential for global dominance. The eps_ttm_co metric reflects net income allocated per share over a trailing twelve-month period, excluding the impact of total issuance volume. The current value of -1.69 allows for a real-time assessment of the actual efficiency of intellectual property capitalization. Monitoring this metric is critical for distinguishing true business resilience from temporary stability. Analyzing this chart of net income per share over 12 months helps investors identify capital dilution risks in a timely manner.